-
Marshall Edwards Announces Publication of Pre-Clinical Studies in Pancreatic Cancer
Monday, June 27, 2011 - 9:07am | 265Marshall Edwards (Nasdaq: MSHL) announced today the publication of results from pre-clinical studies of Triphendiol, a prodrug of the Company's lead drug candidate NV-143, that demonstrate its anti-proliferative activity in pancreatic cancer as both a monotherapy and as a chemosensitizer. The...
-
Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Monday, June 27, 2011 - 9:02am | 114Cardium Therapeutics (NYSE: CXM) today announced that it had entered into an agreement with Transdel Pharmaceuticals to acquire substantially all of Transdel's business assets including a Phase 3 product candidate Ketotransdel, which is a topically-administered analgesic for the treatment of...
-
Piper Jaffray Maintains Overweight on Amylin Pharmaceuticals
Monday, June 27, 2011 - 8:32am | 107Piper Jaffray is out with its report today on Amylin Pharmaceuticals (NASDAQ: AMLN), maintaining Overweight after ECG data was just released from the DURATION 1 Phase III trial of Bydureon. In a note to clients, Piper Jaffray writes, "We believe this ECG data could mitigate concerns related to...
-
Jeffeties Maintains Estimates On Amgen
Monday, June 27, 2011 - 8:28am | 107According to Jefferies, Amgen (NASDAQ: AMGN) estimates are maintained. Jefferies said that updated label removes a specific Hb target range (10-12 g/dL) and guides to individualize ESA therapy to reduce the need for red blood cell transfusions. Also, the label implies Hb target dose of 10-11 g/dL...
-
Benzingas Top Pre-Market NASDAQ Gainers
Monday, June 27, 2011 - 8:13am | 128Icagen Inc (NASDAQ: ICGN) shares advanced 129.59% to $5.51 in the pre-market session. Pfizer(NYSE: PFE) reported that it is considering a strategic transaction with Icagen. Sangamo BioSciences Inc (NASDAQ: SGMO) shares advanced 3.82% to $6.25 in the pre-market session. SGMO had no debt for the...
-
Pharmacoeconomic Value of Addiction Treatments, Including VIVITROL, Published in Leading Healthcare Policy Journal
Monday, June 27, 2011 - 8:11am | 356Alkermes (NASDAQ: ALKS) today announced the publication of two new studies in the June issue of The American Journal of Managed Care1,2 evaluating pharmacoeconomic data on addiction treatments, including VIVITROL® (naltrexone for extended-release injectable suspension), with the endpoint of total...
-
Icagen Rises on M&A Speculation with Pfizer -AP
Monday, June 27, 2011 - 8:06am | 77The Associated Press reports that Icagen (NASDAQ: ICGN) is rising on merger speculation with Pfizer (NYSE: PFE). The Reuters story on the AP article can be found via the link above. At last check, shares of Icagen were trading over 133% higher in pre-market trading versus Friday's closing price.
-
DUSA Pharmaceuticals Added to Russell 3000 Index
Monday, June 27, 2011 - 7:31am | 40DUSA Pharmaceuticals (Nasdaq: DUSA) announced that it has been added to the U.S. broad-market Russell 3000® Index. Russell Investments reconstituted its comprehensive set of U.S. and global equity indexes on June 24, 2011.
-
Jefferies Maintains Buy on Amylin Pharmaceuticals
Monday, June 27, 2011 - 7:25am | 97Jefferies is out with its report today on Amylin Pharmaceuticals (NASDAQ: AMLN), maintaining Buy. In a note to clients, Jefferies writes, "We viewed AMLN's presentations on QT data from DURATION-1 and new data on Byetta once monthly as incremental positives for the stock. We also see the...
-
Seattle Genetics Achieves $5M Milestone Under Millennium Collaboration for European Medicines Agency Acceptance of Brentuximab Vedotin MAA
Monday, June 27, 2011 - 7:01am | 220Seattle Genetics, Inc., (Nasdaq: SGEN) today announced that it will receive a $5 million milestone payment under its brentuximab vedotin (ADCETRISTM) collaboration with Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502). The...
-
Mad Money Lightning Round: Cramer Likes National Grid
Monday, June 27, 2011 - 12:05am | 220On CNBC's Mad Money, Jim Cramer said during the Lightning Round that National Grid (NYSE: NGG) is a “high-yielding utility and I want to stick with it." Cramer said that he “likes Macy's (NYSE: M) but the stock has had a big run and the market's been choppy. I'll give it a thumbs up but the market...
-
30 Stocks for This Week: Investment and Trading Opportunities
Sunday, June 26, 2011 - 11:10pm | 3116Each week I publish stocks to watch for the upcoming week as potential momentum trades or longer-term investments. The stocks below all have a 50k minimum average daily share volume and traded at a 52-week high on strong volume, with a minimum of two times relative volume on Friday, June 24th. In...
-
Mannkind Studies Show No Increased Risk of Cardiac Events in Diabetes Patients Treated with AFREZZA
Friday, June 24, 2011 - 6:33pm | 226MannKind (NASDAQ: MNKD) annouces that the findings of two separate studies further substantiate that treatment with the investigational ultra rapid acting mealtime insulin AFREZZA (insulin human [rDNA origin]) Inhalation Powder does not result in excess cardiovascular events in type 1 or type 2...
-
Options Brief: Oncothyreon Inc.
Friday, June 24, 2011 - 1:07pm | 73Shares of Oncothyreon Inc. (NASDAQ: ONTY) are higher on the session by 8.11%, trading at $9.26. Overall call volume is now running at 2.93x the daily average, with 71% of all calls traded being purchases on the offer. 5,161 contracts have traded on the session so far. Oncothyreon Inc. is a...
-
Amgen Announces Modifications to U.S. Prescribing Information for Use of Erythropoiesis-Stimulating Agents in Chronic Kidney Disease
Friday, June 24, 2011 - 11:52am | 267Amgen (NASDAQ: AMGN) announced today that the U.S. Food and Drug Administration has approved modified language in the prescribing information for the use of erythropoiesis-stimulating agents, including Aranesp® (darbepoetin alfa) and EPOGEN® (Epoetin alfa), in patients with chronic kidney disease...